Daiichi Sankyo unit accuses Pharmacosmos of patent infringement
12-02-2020
AstraZeneca and Daiichi Sankyo to develop new cancer treatment
02-04-2019
Seattle Genetics to acquire biotech company for $614m
02-02-2018
14-11-2019
Pavel Kapysh / Shutterstock.com
Seattle Genetics has asked the American Arbitration Association (AAA) to help resolve a dispute with Daiichi Sankyo, alleging that the Japanese pharma company used its technology to create a number of drugs.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Daiichi Sankyo, American Arbitration Association, Seattle Genetics, trastuzumab deruxtecan, breast cancer, antibody-drug conjugate